Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CStone Files Taiwan NDA for Precision-Med GIST Candidate

publication date: Mar 27, 2020

Suzhou CStone Pharma filed an NDA in Taiwan for avapritinib, a precision therapy for gastrointestinal stromal tumors (GIST). The candidate is indicated for adult patients with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. Avapritinib produced an ORR of 84% in the patient population against a 0% ORR for other TKI drugs. In 2018, CStone in-licensed greater China rights to avapritinib in a $386 million, three-drug deal with Blueprint Medicines of Cambridge, MA. More details....

Stock Symbols: (HK: 2616) (NSDQ: BPMC)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China